Bioinformatic clonality analysis of next-generation sequencing-derived viral vector integration sites

Human Gene Therapy Methods

Volumn 23, Issue 2, 2012, Pages 111-118

  Arens, Anne ^a   Appelt, Jens Uwe ^a   Bartholomae, Cynthia C ^a   Gabriel, Richard ^a   Paruzynski, Anna ^a   Gustafson, Derek ^a   Cartier, Nathalie ^b   Aubourg, Patrick ^b   Deichmann, Annette ^a   Glimm, Hanno ^a   Von Kalle, Christof ^a   Schmidt, Manfred ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ARTICLE; BIOINFORMATICS; CLONAL VARIATION; DNA INTEGRATION; HIGH THROUGHPUT SEQUENCING; HUMAN; MOLECULAR GENETICS; NONHUMAN; PRIORITY JOURNAL; PYROSEQUENCING; VIRUS GENOME; ANIMAL; BIOLOGY; COMPUTER PROGRAM; GENE THERAPY; GENE VECTOR; GENETICS; LENTIVIRINAE; METHODOLOGY; MOUSE; RAT; VIRUS DNA CELL DNA INTERACTION;

MAMMALIA;

ANIMALS; COMPUTATIONAL BIOLOGY; GENETIC THERAPY; GENETIC VECTORS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LENTIVIRUS; MICE; RATS; SOFTWARE; VIRUS INTEGRATION;

EID: 84867744253     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2011.219     Document Type: Article

References (50)

1. Abel, U., Deichmann, A., Bartholomae, C., et al. (2007). Real-time definition of non-randomness in the distribution of genomic events. PLoS One 2, e570.
2. Abel, U., Deichmann, A., Nowrouzi, A., et al. (2011). Analyzing the number of common integration sites of viral vectors - new methods and computer programs. PLoS One 6, e24247.
3. Aiuti, A., Slavin, S., Aker, M., et al. (2002). Correction of ADASCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410-2413.
4. Aiuti, A., Cattaneo, F., Galimberti, S., et al. (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360, 447-458.
5. Appelt, J.U., Giordano, F.A., Ecker, M., et al. (2009). QuickMap: A public tool for large-scale gene therapy vector insertion site mapping and analysis. Gene Ther. 16, 885-893.
6. Bartholomae, C.C., Arens, A., Balaggan, K.S., et al. (2011). Lentiviral vector integration profiles differ in rodent postmitotic tissues. Mol. Ther. 19, 703-710.
7. Bessereau, J.-L. (2006). Transposons in C. elegans. In WormBook. The C. elegans Research Community, ed. Available at http://www.wormbook.org/chapters/ www-transposons/transposons.html
8. Bianchi, M., Hakkim, A., Brinkmann, V., et al. (2009). Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood 114, 2619-2622.
9. Biffi, A., Bartolomae, C.C., Cesana, D., et al. (2011). Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 117, 5332-5339.
10. Boztug K, Schmidt M, Schwarzer A, et al. (2010). Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 363, 1918-1927.
11. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818- 823.
12. Cavazzana-Calvo, M., Payen, E., Negre, O., et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human b-thalassaemia. Nature 467, 318-322.
13. Cavazzana-Calvo, M., Fischer, A., Bushman, F.D., et al. (2011). Is normal hematopoiesis maintained solely by long-term multipotent stem cells? Blood 117, 4420-4424.
14. Copeland, N.G., and Jenkins, N.A. (2010). Harnessing transposons for cancer gene discovery. Nat. Rev Cancer 10, 696-706.
15. de Ridder, J., Uren, A., Kool, J., et al. (2006). Detecting statistically significant common insertion sites in retroviral insertional mutagenesis screens. PLoS Comput. Biol. 2, e166.
16. Dieter, S.M., Ball, C.R., Hoffmann, C.M., et al. (2011). Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 9, 357-365.
17. Gabriel, R., Eckenberg, R., Paruzynski, A., et al. (2009). Comprehensive genomic access to vector integration in clinical gene therapy. Nat. Med. 15, 1431-1436.
18. Gabriel, R., Lombardo, A., Arens, A., et al. (2011). An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nature Biotechnol. 29, 816-823.
19. Gaspar, H.B., Parsley, K.L., Howe, S., et al. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364, 2181-2187.
20. Gillet, N.A., Malani, N., Melamed, A., et al. (2011). The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones. Blood 117, 3113-3122.
21. Glimm, H., Schmidt, M., Fischer, M., et al. (2005). Efficient marking of human cells with rapid but transient repopulating activity in autografted recipients. Blood 106, 893-898.
22. Grez, M., Reichenbach, J., Schwable, J., et al. (2011). Gene therapy of chronic granulomatous disease: The engraftment dilemma. Mol. Ther. 19, 28-35.
23. Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., et al. (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346, 1185- 1193.
24. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419.
25. Hacein-Bey-Abina, S., Garrigue, A., Wang, G.P., et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132-3142.
26. Hacein-Bey-Abina, S., Hauer, J., Lim, A., et al. (2010). Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 363, 355-364.
27. Hawkins, T.B., Dantzer, J., Peters, B., et al. (2011). Identifying viral integration sites using SeqMap 2.0. Bioinformatics 27, 720-722.
28. Howe, S.J., Mansour, M.R., Schwarzwaelder, K., et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118, 3143-3150.
29. Kang, H.J., Bartholomae, C.C., Paruzynski, A., et al. (2011). Retroviral gene therapy for X-linked chronic granulomatous disease: Results from phase I/II trial. Mol. Ther. 19, 2092- 2101.
30. Karolchik, D., Hinrichs, A.S., Furey, T.S., et al. (2004). The UCSC Table Browser data retrieval tool. Nucleic Acids Res. 32, D493-D496.
31. Kent, W.J. (2002). BLAT - the BLAST-like alignment tool. Genome Res. 12, 656-664.
32. Lemischka, I.R., and Jordan, C.T. (2001). The return of clonal marking sheds new light on human hematopoietic stem cells. Nat. Immunol. 2, 11-12.
33. Margulies, M., Egholm, M., Altman, W.E., et al. (2005). Genome sequencing in microfabricated high-density picolitre reactors. Nature 437, 376-380.
34. Matrai, J., Cantore, A., Bartholomae, C.C., et al. (2011). Hepatocytetargeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. Hepatology 53, 1696-1707.
35. Mitchell, R.S., Beitzel, B.F., Schroder, A.R., et al. (2004). Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2, e234.
36. Mueller, P.R., and Wold, B. (1989). In vivo footprinting of a muscle specific enhancer by ligation mediated PCR. Science 246, 780-786.
37. Newman, M., and Lardelli, M. (2010). A hyperactive Sleeping Beauty transposase enhances transgenesis in zebrafish embryos. BMC Res. Notes 3, 282.
38. Noonan, J.P., Coop, G., Kudaravalli, S., et al. (2006). Sequencing and analysis of Neanderthal genomic DNA. Science 314, 1113- 1118.
39. Ott, M.G., Schmidt, M., Schwarzwaelder, K., et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12, 401-409.
40. Paruzynski, A., Arens, A., Gabriel, R., et al. (2010). Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat. Protoc. 5, 1379-1395.
41. Paruzynski, A., Boztug, K., Ball, C., et al. (2011). Molecular follow-up of the German WAS clinical gene therapy trial [abstract 343]. Mol. Ther. 19, S133.
42. Pruitt, K.D., Tatusova, T., Klimke, W., et al. (2009). NCBI Reference Sequences: Current status, policy and new initiatives. Nucleic Acids Res. 37, D32-D36.
43. Schmidt, M., Hacein-Bey-Abina, S., Wissler, M., et al. (2005). Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. Blood 105, 2699- 2706.
44. Schmidt, M., Schwarzwaelder, K., Bartholomae, C., et al. (2007). High-resolution insertion-site analysis by linear amplificationmediated PCR (LAM-PCR). Nat. Methods 4, 1051-1057.
45. Schroder, A.R., Shinn, P., Chen, H., et al. (2002). HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521-529.
46. Silver, J., and Keerikatte, V. (1989). Novel use of polymerase chain reaction to amplify cellular DNA adjacent to an integrated provirus. J. Virol. 63, 1924-1928.
47. Stein, S., Ott, M.G., Schultze-Strasser, S., et al. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16, 198-204.
48. Suzuki, T., Shen, H., Akagi, K., et al. (2002). New genes involved in cancer identified by retroviral tagging. Nat. Genet. 32, 166-174.
49. Wu, X., Li, Y., Crise, B., et al. (2003). Transcription start regions in the human genome are favored targets for MLV integration. Science 300, 1749-1751.
50. Yla? -Herttuala, S. (2011). Gene therapy moves forward in 2010. Mol. Ther. 19, 219-220.